Building the First CAR T Company

2020-02-07 · 29 min · episode 519 · 12 entities

episode page audio

Asserted relationships

→ hosted by Andreessen Horowitz person

0.55

evidence rules-v4
Feed author/publisher: Andreessen Horowitz
→ discusses Science concept

0.40

evidence rules-v4
Feed category: Science
→ discusses Technology concept

0.40

evidence rules-v4
Feed category: Technology
→ discusses Business concept

0.40

evidence rules-v4
Feed category: Business
→ discusses Entrepreneurship concept

0.40

evidence rules-v4
Feed category: Entrepreneurship
→ hosted by a16z company

0.40

evidence rules-v4
Feed author/publisher: a16z

Entities found in this episode

concepts 9

mentioned Science concept

0.50

evidence rules-v4
Feed category: Science
mentioned Technology concept

0.50

evidence rules-v4
Feed category: Technology
mentioned Business concept

0.50

evidence rules-v4
Feed category: Business
mentioned Entrepreneurship concept

0.50

evidence rules-v4
Feed category: Entrepreneurship
discusses Science concept

0.40

evidence rules-v4
Feed category: Science
discusses Technology concept

0.40

evidence rules-v4
Feed category: Technology
discusses Business concept

0.40

evidence rules-v4
Feed category: Business
discusses Entrepreneurship concept

0.40

evidence rules-v4
Feed category: Entrepreneurship
mentioned CAR concept

0.35

evidence rules-v4
CAR

persons 2

mentioned Andreessen Horowitz person

0.70

evidence rules-v4
Feed author/publisher: Andreessen Horowitz
hosted by Andreessen Horowitz person

0.55

evidence rules-v4
Feed author/publisher: Andreessen Horowitz

companys 1

hosted by a16z company

0.40

evidence rules-v4
Feed author/publisher: a16z

Episode description as stored

with @OzAzamTmunity1, @JorgeCondeBio, and @omnivorousread CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential cure. But this isn't just one new medicine, it's an entirely new therapeutic tool—and a total paradigm shift from most traditional medicines we've seen before. Tmunity CEO Usman "Oz" Azam was previously the head of Cell and Gene Therapies at Novartis, in many ways the first CAR T company and the team brought us blood cancer CAR T-cell therapy Kymriah—the first cell-based gene therapy to be approved in the US. In this conversation, Azam discusses with a16z's general partner Jorge Conde and Hanne Tidnam what CAR T therapy really is and how it all works. The conversation begins with the “patient and cell journey” of this treatment and how this medicine is developed, manufactured, delivered to patients; why exactly it's so different traditional medicines; what it will take to make these new medicines work on more kinds of cancer, scale to more patients, and cost less; and finally, what company building lessons can be learned from building the first CAR T company of its kind from the ground up. This episode was recorded at the annual a16z Summit. Stay Updated: Find a16z on YouTube: YouTube Find a16z on X Find a16z on LinkedIn Listen to the a16z Show on Spotify Listen to the a16z Show on Apple Podcasts Follow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.